(S)-4-(2-(2-carboxyacetoxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide → (S)-4-(2-(3-(4-(N-(tert-butoxycarbonyl)-methylsulfonamido)-3-(cyclopropylmethoxy)benzyloxy)-3-oxopropanoyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide

HRID 1776489Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1776489
[C:1]([CH2:4][C:5]([O:7][C@H:8]([C:19]1[CH:24]=[CH:23][C:22]([O:25][CH:26]([F:28])[F:27])=[C:21]([O:29][CH2:30][CH:31]2[CH2:33][CH2:32]2)[CH:20]=1)[CH2:9][C:10]1[C:15]([Cl:16])=[CH:14][N+:13]([O-:17])=[CH:12][C:11]=1[Cl:18])=[O:6])([OH:3])=[O:2].[CH:34]1([CH2:37][O:38][C:39]2[CH:44]=[C:43]([CH2:45]O)[CH:42]=[CH:41][C:40]=2[N:47]([S:55]([CH3:58])(=[O:57])=[O:56])[C:48](=[O:54])[O:49][C:50]([CH3:53])([CH3:52])[CH3:51])[CH2:36][CH2:35]1>CN(C1C=CN=CC=1)C.CN(C=O)C>[C:50]([O:49][C:48]([N:47]([C:40]1[CH:41]=[CH:42][C:43]([CH2:45][O:2][C:1](=[O:3])[CH2:4][C:5]([O:7][C@H:8]([C:19]2[CH:24]=[CH:23][C:22]([O:25][CH:26]([F:28])[F:27])=[C:21]([O:29][CH2:30][CH:31]3[CH2:32][CH2:33]3)[CH:20]=2)[CH2:9][C:10]2[C:15]([Cl:16])=[CH:14][N+:13]([O-:17])=[CH:12][C:11]=2[Cl:18])=[O:6])=[CH:44][C:39]=1[O:38][CH2:37][CH:34]1[CH2:35][CH2:36]1)[S:55]([CH3:58])(=[O:56])=[O:57])=[O:54])([CH3:53])([CH3:51])[CH3:52]

Komponenten

5

Edukt 2

HCID 86679438(S)-4-(2-(2-carboxyacetoxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxideHCID 86679440Tert-butyl 2-(cyclopropylmethoxy)-4-(hydroxymethyl)phenyl(methylsulfonyl)carbamate

Produkt 1

HCID 86679439(S)-4-(2-(3-(4-(N-(tert-butoxycarbonyl)-methylsulfonamido)-3-(cyclopropylmethoxy)benzyloxy)-3-oxopropanoyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 142844-(Dimethylamino)pyridineKatalysatorHCID 6228DimethylformamideLösungsmittel

Versuchsvorschrift

A mixture of (S)-4-(2-(2-carboxyacetoxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (50 mg, 0.099 mmol), tert-butyl 2-(cyclopropylmethoxy)-4-(hydroxymethyl)phenyl-(methylsulfonyl)-carbamate (73 mg, 0.2 mmol), DMAP (14.5 mg, 0.12 mmol), and ECD (57 mg, 0.3 mmol) in DMF (1.5 ml) was stirred at RT overnight. The reaction mixture was quenched with water, and the product was extracted with EtOAc. The organic phase was washed with HCl 1M, NaHCO3 sat. sol. and brine. The organic layer was dried over Na2SO4 and evaporated to dryness. The crude (70 mg) was used for the next step without any further purification.

Aufarbeitung

  1. customThe reaction mixture was quenched with water
  2. extractionthe product was extracted with EtOAc
  3. washThe organic phase was washed with HCl 1M, NaHCO3 sat. sol. and brine
  4. dry with materialThe organic layer was dried over Na2SO4
  5. customevaporated to dryness
  6. customThe crude (70 mg) was used for the next step without any further purification

Quellen und Nachweise

ORD-Eintrag
ord-7f998f934b294e5795b6498f3ad3768f
Quelldatensatz
uspto-grants-2016_02
Patentnummer
US09265768B2

Notizen zur Reaktion

Wird geladen…